PT -期刊文章盟Takayoshi Shimohata AU -郁子Aiba盟Mari吉田盟Yasuko Toyoshima AU - Shigeo Murayama盟——Uchihara AU - Arai Tetsuaki盟一郎长谷川合子Yabe AU -长谷川Takafumi盟盟- Ikeuchi武盟Masato长谷川AU -隆小森盟Koichi若林史江盟阿雅Tokumaru AU -凯塔樱井非盟-吴克群中岛美嘉盟J-VAC研究小组TI -背景病理学corticobasal变性(CBD)模仿的日本验证研究CBD (J-VAC研究)——(P6.070) DP - 2018年4月10 TA -神经病学PG - P6.070 VI - 90 IP - 15补充4099 - //www.ez-admanager.com/content/90/15_Supplement/P6.070.short 4100 - //www.ez-admanager.com/content/90/15_Supplement/P6.070.full所以Neurology2018 4月10;首页90 AB -目的:确定日本的背景病理患者“corticobasal变性(CBD)模仿”。背景:最近的研究集中在疾病修饰治疗CBD的发展,目标主要是在τ功能障碍。CBD的准确诊断越来越重要,但一个主要限制之间的临床表型相似性CBD和CBD模仿其他病理造成的。设计/方法:患者对他们详细的临床病理的研究结果,在那些被诊断为临床CBD中央审查期间或corticobasal综合症(CBS)。评估项目包括发病年龄、年龄在死亡时间,最终的临床诊断和临床体征和症状表现和在整个临床过程。结果:我们发现30病理确诊患者11日本机构。发病年龄为67.3±9.9 (±SD)年。疾病持续时间为7.5±2.9年。病理分析表明,进行性核上的麻痹(PSP)是最常见的诊断(37%),其次是阿尔茨海默病(广告;20%),球状胶质tauopathies (GGT; 7%), and other diseases including dementia with Lewy bodies (DLB), Pick disease, frontotemporal lobar degeneration (FTLD)-TDP or FUS, prion disease and glioblastoma.Conclusions: ‘CBD mimics’ include 4 repeat tauopathies (PSP and GGT; 43%), non-4 repeat tauopathies (AD, Pick disease; 23%) and other diseases (DLB, FTLD, prion disease and glioblastoma etc.). Because disease-modifying treatments for CBD may also be beneficial for 4 repeat tauopathies, exclusion of non-4 repeat tauopathies and other diseases are absolutely necessary.Disclosure: Dr. Shimohata has nothing to disclose. Dr. Aiba has nothing to disclose. Dr. Yoshida has nothing to disclose. Dr. Toyoshima has nothing to disclose. Dr. Murayama has nothing to disclose. Dr. Uchihara has nothing to disclose. Dr. Arai has nothing to disclose. Dr. Yabe has nothing to disclose. Dr. Hasegawa has nothing to disclose. Dr. Hasegawa has nothing to disclose. Dr. Ikeuchi has nothing to disclose. Dr. Hasegawa has nothing to disclose. Dr. Komori has nothing to disclose. Dr. Wakabayashi has nothing to disclose. Dr. Tokumaru has nothing to disclose. Dr. Sakurai has nothing to disclose. Dr. Nakashima has nothing to disclose.